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Fig 1. Kaplan-Meier curves showing peripheral vascular intervention
(PVI) reinterventions for patients who underwent index fcmoropoplitcal atherectomy versus nonatherectomy for the treatment of
claudication.

therapy, as well as exercise therapy and smoking cessation. Although evidence supports medical and lifestyle management of PAD before surgical intervention, it is currently unclear whether clinical practice reﬂects
this. Moreover, it is also unknown whether variability in medical and lifestyle optimization before revascularization affects short- and long-term
outcomes. This study was conducted to determine the proportion of patients actively receiving evidence-based medical and lifestyle therapy at
the time of surgery in a regional hospital network and whether receipt
of therapy affected outcomes.
Methods: We conducted a retrospective study of adult patients undergoing elective open lower extremity bypass for claudication, rest pain, or
tissue loss from 2012 to 2021 within a large, statewide, 35 hospital quality
registry. The primary exposures were preoperative medical therapy (speciﬁcally antiplatelet agents, statins, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and cilostazol) and lifestyle
management including supervised exercise therapy and participation
in smoking cessation counseling. The primary outcomes were 30-day
and 1-year mortality, hospital readmission, amputation, wound complications, myocardial infarction, nonpatent bypass, and nonambulatory functional status. Multivariable logistic regression was performed to estimate
the association of receiving some or all recommended therapy on
outcomes.
Results: There were 10,278 patients who underwent bypass surgery
during the study period, with a mean age of 65.8 6 10.4 years; 7036 patients (68.5%) were male. The prevalence of medical and lifestyle management at the time of surgery was variable (Figure). Of the original
cohort, 30-day follow-up data were available for 9664 patients (94.0%
follow-up rate) and 1-year follow-up data were available for 7341 patients (71.4% 1-year follow-up rate). Among patients on relevant medications at discharge, at 30 days, 96.8% were still taking antiplatelet agents,
96.7% were still taking statins, 86.5% were still taking angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, and 24.7% of
patients who received smoking cessation therapy had quit smoking.
Compared with patients on no therapy, patients on some therapy
had signiﬁcantly lower odds of amputation at 30 days (adjusted odds
ratio [aOR], 0.61; 95% conﬁdence interval [CI], 0.38-1.00). At 1 year, there
was no signiﬁcant association between being on some or all therapy
and any outcomes; however, similar trends were observed for amputation (some therapy: aOR, 0.64 [95% CI, 0.39-1.04]; all therapy: aOR, 0.48
[95% CI, 0.22-1.04]).
Conclusions: Although medical and lifestyle management are recommended as ﬁrst-line treatments for patients with PAD, preoperative
adherence to these recommendations was highly variable. Patients
actively receiving preoperative treatment seem to have a lower risk of
subsequent amputation after surgery. This suggests that not only are
there signiﬁcant opportunities to improve adherence to evidencebased treatment of PAD, but that doing so may beneﬁt patients
postoperatively.

Fig 2. Kaplan-Meier curves showing peripheral vascular intervention
(PVI) reinterventions for patients who underwent index femoropoplitcal PVI by an inlier (quartile 1-3) versus outlier (quartile 4)
physician.
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Background: First-line treatment of peripheral arterial disease (PAD) involves medical therapy and lifestyle modiﬁcation. Speciﬁcally, the 2016
American Heart Association/American College of Cardiology guidelines
for the management of PAD make Class I recommendations for antiplatelet therapy, statin therapy, antihypertensive therapy, and cilostazol

Fig. Prevalence of smoking cessation therapy calculated among 4916
current smokers.
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Background: In the setting of increasing “off-label” use of aortic devices, such as physician-modiﬁed devices, recent Vascular Quality Initiative (VQI) studies demonstrate high mortality following endovascular
repair of TAAA, with increased mortality in patients with more extensive disease. US Food and Drug Administration-approved investigational device exemption (IDE) studies, performed at 10 high-volume
aortic centers within the US Aortic Research Consortium (ARC), allow
controlled implementation of investigational technologies for treatment of complex TAAA using purpose-built devices. The aim of this
study is to compare outcomes of IDE patients compared with patients
within the VQI registry.
Methods: A retrospective review was conducted with the VQI registry
(containing no IDE devices) and the ARC registry of all patients who underwent elective complex endovascular treatment of asymptomatic nontraumatic aneurysmal disease involving the visceral aorta between 2011
and 2019. The extent of aneurysmal disease was categorized using

standard Crawford extent deﬁnitions based on graft deployment zones.
Mortality was evaluated with Kaplan-Meier survival analysis.
Results: A total of 3212 patients were evaluated; 51% were from the ARC
database and 49% were from the VQI registry. Table I demonstrates the
extent of disease between the VQI and ARC. Compared with the VQI, the
ARC cohort had signiﬁcantly higher proportion of extent 2 and extent 4
aneurysms. Baseline maximal aneurysm diameters did not vary signiﬁcantly by extent of aneurysm between the cohorts. compared with the
VQI, male gender, coronary artery disease, and chronic obstructive pulmonary disease were more prevalent within the ARC cohort, whereas
end-stage renal disease was less prevalent within the ARC cohort. Mortality at 30 days across all extents was signiﬁcantly higher in the VQI
compared with ARC (6.7% vs 2.2%; P < .001). Similarly, 1-year mortality
was signiﬁcantly higher in the VQI cohort compared with the ARC cohort
(14.3% vs 10.2%; P < .001) (Table II). Mortality within aneurysms isolated
below the diaphragm (extent 4) was signiﬁcantly higher within the VQI
compared with ARC at both 30 days (6.1% VQI vs 2% ARC; P < .001)
and 1 year (12.3% VQI vs 8.4% ARC; P ¼ .005). Similarly, mortality in aneurysms involving the thoracic aorta (extent: 1, 2, 3, and 5) was signiﬁcantly
higher in the VQI compared with ARC at both 30 days (7.3% VQI vs
2.6% ARC; P < .001) and 1 year (16.3% vs 13.1%; P ¼ .035).
Conclusions: Across both the ARC and VQI cohorts, patients with more
extensive aortic disease treated with endovascular approaches have
poorer survival. Compared with the VQI, patients in the ARC database
have improved survival after repair, regardless of disease extent despite
an older patient population, and similar comorbidity proﬁle. These differences may be due to the highly selective nature of IDE studies within the
ARC, improved outcomes in high-volume centers with dedicated aortic
teams and a focus on complex aortic disease, and/or an unmeasured
beneﬁt of custom aortic devices and repair techniques.
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Table I. Baseline anatomic and procedural details between the Aortic Research Consortium (ARC) and Vascular Quality Initiative (VQI) cohorts
All (n ¼ 3212)

VQI Cohort (n ¼ 1571)

ARC Cohort (n ¼ 1641)

219 (6.8)

172 (10.9)

47 (2.9)

Type 2

532 (16.6)

229 (14.6)

303 (18.5)

Type 3

482 (15.0)

238 (15.1)

244 (14.9)

Type 4

1827 (56.9)

802 (51.1)

1025 (62.5)

Type 5

152 (4.7)

130 (8.3)

22 (1.3)

Type 1

P value
<.001

Aneurysm extent

Maximal aneurysm diameter (mm)
Type 1

63.6 6 10.9

63.9 6 13.9

64.5 6 11.3

Type 2

64.2 6 10.9

65.8 6 11.9

63.9 6 10.1

.055

Type 3

64.7 6 10.1

64.0 6 9.7

65.4 6 10.9

.137

Type 4

62.8 6 10.6

62.3 6 10.2

63.8 6 11.4

.112

Type 5

62.5 6 10.1

62.0 6 9.8

64.5 6 7.3

.575

72.3 6 8.9

73.4 6 7.9

<.001

Male gender

2197 (68.4)

1027 (65.4)

1170 (71.3)

<.001

Caucasian race

2736 (85.3)

1267 (80.6)

1469 (89.8)

<.001

HTN

2930 (91.3)

1438 (91.5)

1492 (90.9)

.394

CAD

1188 (37.0)

442 (28.1)

746 (45.5)

<.001

CHF

430 (13.4)

223 (14.2)

207 (12.6)

.195

COPD

1211 (32.7)

660 (20.3)

551 (17.2)

<.001

53 (3.4)

24 (1.5)

<.001

1377 (87.7)

1430 (87.6)

.442

Demographics
Age

ESRD
History of smoking

77 (2.4)
2807 (87.6)

.944

BMI, Body mass index; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; ESRD, end-stage
renal disease; HTN, hypertension.
Values are number (%) or mean 6 standard deviation.

